In conclusion, our study revealed that YL-0919, a triple-target compound acting as an SSRI, a 5-HT1A receptor partial agonist and a 5-HT6 receptor full agonist, exerted a significant anti-PTSD effects partially mediated by ameliorating the structural neuroplasticity by increasing the expression of BDNF and the formation of synaptic proteins in the PFC. Here, BDNF is linked to post-traumatic stress disorder.